Amino Acid, Peptide, or Protein – Page 60

AVEO Oncology’s Fotivda Combo Fails to Meet Primary Endpoint in Phase III Renal Cell Carcinoma Study

9 months ago talkbio0Tagged AVEO, Fotivda, Malignant neoplasm of kidney, Neoplasms, nivolumab, Phase 3 Clinical Trials, Renal Cell Carcinoma, tivozanib

AVEO Oncology, Fotivda, tivozanib, renal cell carcinoma, Phase III clinical trial, TiNivo-2 study, nivolumab, Opdivo, kidney cancer

J&J Abandons Addex-Partnered Epilepsy Candidate After Phase II Failure

9 months ago talkbio0Tagged Epilepsy, Johnson & Johnson, nervous system disorder, Phase 2 Clinical Trials, Receptors, Metabotropic Glutamate

Addex Therapeutics, Johnson & Johnson, ADX71149, Epilepsy, Phase II Trial, Metabotropic Glutamate Receptor, Neurological Disorders

FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search

10 months ago talkbio0Tagged Accelerated, Agenus, Approved, balstilimab, Botensilimab, Colorectal Carcinoma, Combined, Immunotherapy, Partnership, Phase 3 Clinical Trials, United States Food and Drug Administration

Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership

CordenPharma Invests €900M in Peptide Manufacturing Expansion to Meet Rising Demand for GLP-1 Medications

10 months ago talkbio0Tagged CordenPharma, Diabetes, Drug Industry, expansion, Glucagon-Like Peptide 1, Investments, Obesity, Peptides

CordenPharma, GLP-1, peptide manufacturing, expansion, investment, diabetes, obesity, pharmaceutical industry

FDA Rejects Novo Nordisk’s Once-Weekly Insulin Icodec for Diabetes Treatment

10 months ago talkbio0Tagged Complete, Diabetes, Diabetes Mellitus, Non-Insulin-Dependent, Icodec, Insulin, Nordisk, Response process, United States Food and Drug Administration, Weekly

FDA, Novo Nordisk, Icodec, Weekly Insulin, Diabetes Treatment, Type 1 Diabetes, Type 2 Diabetes, Complete Response Letter

FTC to Sue Major PBMs Over Insulin and Drug Prices Amid Anticompetitive Concerns

10 months ago talkbio0Tagged anticompetitive, Benefit, health companies, Insulin, legal action, manager, PBMs, Pharmaceutical Services, Practice Experience, Prices, United States Federal Trade Commission

FTC, PBMs, Insulin Prices, Drug Prices, Anticompetitive Practices, Pharmacy Benefit Managers, Health Companies, Legal Action

Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment

10 months ago talkbio0Tagged Biological Response Modifier Therapy, Dermatitis, Atopic, Ebglyss, England, lebrikizumab, Moderate (severity modifier), Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Recommendation, Severe (severity modifier)

Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis

Pfizer’s R&D Chief Mikael Dolsten to Step Down After 15 Years of Leadership

10 months ago talkbio0Tagged COVID19 (disease), development aspects, Mikael, Pfizer, research, Scientific Officer, Successor Search, Vaccines

Pfizer, Mikael Dolsten, Chief Scientific Officer, Research and Development, COVID-19 Vaccine, Successor Search

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

10 months ago talkbio0Tagged AMT-130, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, neurofilament protein L, NfL, Phase I/II trials, Regenerative Medicine, RMAT, Unified - Type of Agreement, UniQure

uniQure, Huntington’s disease, AMT-130, gene therapy, Phase I/II trials, disease progression, neurofilament light protein (NfL), Unified Huntington’s Disease Rating Scale (cUHDRS), Regenerative Medicine Advanced Therapy (RMAT) designation

HilleVax Discontinues Norovirus Vaccine for Infants After Mid-Stage Trial Failure

10 months ago talkbio0Tagged Discontinuation (procedure), Failure (biologic function), HilleVax, Infant, mid-stage trial, Norovirus, Vaccines

HilleVax, norovirus vaccine, infants, mid-stage trial, failure, discontinuation